Latest Commercialization News

Yancoal Australia posted a record 38.6 million tonnes of attributable saleable coal in 2025, up 5% on 2024, but net profit after tax plunged 64% to A$440 million amid softer coal prices. The miner maintained disciplined cost control and declared A$769 million in fully franked dividends.

Pinnacle Minerals has exited its US critical minerals ventures, retaining key Australian and Canadian assets while bolstering its board and cash position to pursue strategic growth.

Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.

AXP Energy's Charlie #1 well in Oklahoma has reached an initial production rate of 45 barrels of oil equivalent per day, with first oil sales completed, marking a key transition to revenue generation.

Papyrus Australia (ASX: PPY) has secured $175,000 through a share placement alongside convertible note conversions and related party loans, aiming to fund commercialisation and fulfil a key contract for biodegradable Collar Keeper® products.

Omega Oil and Gas has secured A$60 million in a strongly oversubscribed institutional placement to fund an upgraded drilling program featuring US-standard horizontal wells and extended flow testing in Queensland’s Taroom Trough.

InteliCare has inked a $200,000 contract to deploy its AI-powered monitoring platform across 65 retirement villas at Warrigal's new development, marking its first foray into the retirement living sector with potential for wider rollout.

BPH Global’s Indonesian arm has entered Stage 2 of its collaboration with Indonesia’s National Research and Innovation Agency to develop fucoidan extraction technology and a powdered supplement prototype, targeting commercialisation within months.

First Graphene has demonstrated a significant carbon reduction in cement roof tiles through a UK production trial with FP McCann, using graphene-enhanced cement to lower emissions and material use.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.

Delta Lithium’s March quarter report highlights robust high-grade lithium drilling at Mt Ida, successful production of battery-grade lithium and rubidium carbonates, and ongoing exploration progress at Yinnetharra, supported by a strong $52 million cash position.

Macro Mining Services has partnered with Austral Pacific to tap into gold tailings and stockpiles at the Paris Gold Mine, aiming to turn historical waste into revenue through a 50:50 profit share after expense recovery.